Clinical trial results:
An Open Label, Randomized, Single Dose, Two-Way Crossover Bioequivalence Study Comparing a New 80 Milligram (2x40 mg) Pediatric Appropriate Formulation to an 80 Milligram Commercial Atorvastatin Calcium Tablet Formulation in Healthy Subjects

Summary

EudraCT number	2012-000706-30
Trial protocol	Outside EU/EEA
Global end of trial date	06 March 2009

Results information

Result version number	v1 (current)
This version publication date	13 April 2016
First version publication date	29 July 2015

Trial information

Trial identification

Sponsor protocol code	A2581175

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT00758004
WHO universal trial number (UTN)	-

Notes:

Sponsors

Sponsor organisation name	Pfizer Inc.
Sponsor organisation address	235 E 42nd Street, New York, United States, NY 10017
Public contact	Pfizer ClinicalTrials.gov Call Center, Pfizer Inc., 001 8007181021, ClinicalTrials.gov_Inquiries@pfizer.com
Scientific contact	Pfizer ClinicalTrials.gov Call Center, Pfizer Inc., 001 8007181021, ClinicalTrials.gov_Inquiries@pfizer.com

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	Yes
EMA paediatric investigation plan number(s)	EMEA-000073-PIP01-07
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	27 July 2009
Is this the analysis of the primary completion data?	No

Global end of trial reached?	Yes
Global end of trial date	06 March 2009
Was the trial ended prematurely?	No

Notes:

General information about the trial

Main objective of the trial:

To determine whether 80 milligram (mg) (2x40 mg) of the new formulation atorvastatin calcium chewable tablets were bioequivalent to one 80 mg commercial atorvastatin calcium tablet (Lipitor).

Protection of trial subjects:

The study was in compliance with the ethical principles derived from the Declaration of Helsinki and in compliance with all International Conference on Harmonization (ICH) Good Clinical Practice (GCP) Guidelines. All the local regulatory requirements pertinent to safety of trial subjects were followed.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	13 October 2008
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	No

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	United States: 76
Worldwide total number of subjects	76
EEA total number of subjects	0

Notes:

Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	76
From 65 to 84 years	0
85 years and over	0

Subject disposition

Recruitment

Recruitment details: -

Pre-assignment

Screening details:

Total 76 subjects were enrolled in a single center of United States. Of these 76 subjects, only 75 subjects were treated. Study started from 13 October 2008 and completed on 06 March 2009.

Period 1

Period 1 title	First Intervention Period
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Not blinded

Arms

Are arms mutually exclusive?	Yes
Arm title	New Atorvastatin Then Commercial Atorvastatin

Arm description:

Two chewable tablets of new atorvastatin were administered on Day 1 of first intervention period of 5 da ys. A washout period of at least 14 days was maintained between the two periods.

Arm type	Experimental
Investigational medicinal product name	New Atorvastatin
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Chewable tablet
Routes of administration	Oral use

Dosage and administration details:

Subjects received two 40 mg (80 mg) new atorvastatin calcium chewable tablets.

Arm title	Commercial Atorvastatin Then New Atorvastatin

Arm description:

A single tablet of commercial atorvastatin was administered on Day 1 of first intervention period of 5 da ys. A washout period of at least 14 days was maintained between the two periods.

Arm type	Active comparator
Investigational medicinal product name	Commercial Atorvastatin
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

Subjects received a single commercial atorvastatin calcium tablet of 80 mg .

Number of subjects in period 1	New Atorvastatin Then Commercial Atorvastatin	Commercial Atorvastatin Then New Atorvastatin
Started	39	37
Completed	38	32
Not completed	1	5
Adverse event	1	2
Unspecified	-	3

Period 2	
Period 2 title	Washout Period (At Least 14 Days)
Is this the baseline period?	No
Allocation method	Randomised - controlled
Blinding used	Not blinded

Arms

Are arms mutually exclusive?	Yes
Arm title	New Atorvastatin Then Commercial Atorvastatin

Arm description:

Two new atorvastatin calcium chewable tablets administered on Day 1 of each of the two treatment periods of 5 days. A washout period of at least 14 days was maintained between the two periods

Arm type	No intervention

No investigational medicinal product assigned in this arm

Arm title	Commercial Atorvastatin Then New Atorvastatin

Arm description:

Single commercial atorvastatin calcium tablet administered on Day 1 of each of the two treatment periods of 5 days. A washout period of at least 14 days was maintained between the two periods.

Arm type	No intervention

No investigational medicinal product assigned in this arm

Number of subjects in period 2	New Atorvastatin Then Commercial Atorvastatin	Commercial Atorvastatin Then New Atorvastatin
Started	38	32
Completed	38	32

Period 3

Period 3 title	Second Intervention Period
Is this the baseline period?	No
Allocation method	Randomised - controlled
Blinding used	Not blinded

Arms

Are arms mutually exclusive?	Yes
Arm title	New Atorvastatin Then Commercial Atorvastatin

Arm description:

Two chewable tablets of new atorvastatin were administered on Day 1 of first intervention period of 5 da ys. A washout period of at least 14 days was maintained between the two periods.

Arm type	Active comparator
Investigational medicinal product name	Commercial Atorvastatin
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

Subjects received a single commercial atorvastatin calcium tablet of 80 mg .

Arm title	Commercial Atorvastatin Then New Atorvastatin

Arm description:

Subjects who received commercial atorvastatin in the first intervention period, were administered with t wo chewable tablets of new atorvastatin on Day 1 of second intervention period of 5 days.

Arm type	Experimental
Investigational medicinal product name	New Atorvastatin
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Chewable tablet
Routes of administration	Oral use

Dosage and administration details:

Subjects received two 40 mg (80 mg) new atorvastatin calcium chewable tablets.

Number of subjects in period 3	New Atorvastatin Th en Commercial Ator vastatin	Commercial Atorvast atin Then New Atorv astatin
Started	38	32
Completed	38	32

Baseline characteristics

Reporting groups	
Reporting group title	First Intervention Period

Reporting group description: -

Reporting group values	First Intervention Period	Total	
Number of subjects	76	76	
Age categorical Units: Subjects			
Age continuous Units: years arithmetic mean standard deviation	 35.9 ± 9	 -	
Gender categorical Units: Subjects			
Female	17	17	
Male	59	59	

End points

End point values	New Atorvastatin	Commercial Atorvastatin		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	73	75		
Units: nanogram*hour per milliliter (ng*hr/mL)				
geometric mean (geometric coefficient of variation)	128.2 (± 43)	121.3 (± 41)		

Statistical analyses

Statistical analysis title	AUClast

Statistical analysis description:

Natural log transformed AUClast of atorvastatin was analyzed using a mixed effect model with sequence, period and treatment as a fixed effects and subject within sequence as a random effect. The adjusted mean differences and 90% confidence intervals (CIs) for the differences were exponentiated to provide estimates of the ratio of adjusted geometric means (New/Commercial) and 90% CIs for the ratios.

Comparison groups	New Atorvastatin v Commercial Atorvastatin
Number of subjects included in analysis	148
Analysis specification	Pre-specified
Analysis type	equivalence
Parameter estimate	Percent geometric mean (GM) ratio
Point estimate	105.55
Confidence interval	
level	90 %
sides	2-sided
lower limit	100.34
upper limit	111.03

Primary: Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUCinf) of Atorvastatin

End point title	Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUCinf) of Atorvastatin

End point description:

AUC (0 -- ∞)= Area under the plasma concentration versus time curve (AUC) from time zero (pre -dose) to extrapolated infinite time (0 - ∞). It is obtained from AUC (0 -- t) plus AUC (t - ∞). The PK concentration population was defined as all subjects randomized and treated who have at least 1 concentration in at least 1 treatment period.

End point type	Primary

End point timeframe:

Day 1 pre
-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 9, 12, 24, 36, 48, 72 hours post dose in Period 1 and Period 2

End point values	New Atorvastatin	Commercial Atorvastatin		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	73	75		
Units: ng*hr/mL				
geometric mean (geometric coefficient of variation)	131.9 (± 41)	124.5 (± 40)		

Statistical analyses

Statistical analysis title	Statistical analysis for AUCinf

Statistical analysis description:

Natural log transformed AUCinf of atorvastatin was analyzed using a mixed effect model with sequence, period and treatment as a fixed effects and subject within sequence as a random effect. The adjusted mean differences and 90% confidence intervals (CIs) for the differences were exponentiated to provide estimates of the ratio of adjusted geometric means (New/Commercial) and 90% CIs for the ratios.

Comparison groups	New Atorvastatin v Commercial Atorvastatin
Number of subjects included in analysis	148
Analysis specification	Pre-specified
Analysis type	equivalence
Parameter estimate	Percent GM ratio
Point estimate	105.73
Confidence interval	
level	90 %
sides	2-sided
lower limit	100.69
upper limit	111.02

Primary: Maximum Observed Plasma Concentration (Cmax) of Atorvastatin

End point title	Maximum Observed Plasma Concentration (Cmax) of Atorvastatin

End point description:

The PK concentration population was defined as all subjects randomized and treated who have at least 1 concentration in at least 1 treatment period.

End point type	Primary

End point timeframe:

Day 1 pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 9, 12, 24, 36, 48, 72 hours post dose in Period 1 and Period 2

End point values	New Atorvastatin	Commercial Atorvastatin		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	73	75		
Units: nanogram per milliliter (ng/mL)				
geometric mean (geometric coefficient of variation)	29.23 (± 49)	28.94 (± 50)		

Statistical analyses

Statistical analysis title	Statistical analysis for Cmax
Statistical analysis description:	
Natural log transformed Cmax of atorvastatin was analyzed using a mixed effect model with sequence, period and treatment as a fixed effects and subject within sequence as a random effect. The adjusted mean differences and 90% confidence intervals (CIs) for the differences were exponentiated to provide estimates of the ratio of adjusted geometric means (New/Commercial) and 90% CIs for the ratios.	
Comparison groups	New Atorvastatin v Commercial Atorvastatin
Number of subjects included in analysis	148
Analysis specification	Pre-specified
Analysis type	equivalence
Parameter estimate	Percent GM ratio
Point estimate	101.37
Confidence interval	
level	90 %
sides	2-sided
lower limit	92.39
upper limit	111.23

Secondary: Time to Reach Maximum Observed Plasma Concentration (Tmax) of Atorvastatin

End point title	Time to Reach Maximum Observed Plasma Concentration (Tmax) of Atorvastatin
End point description:	
The PK concentration population was defined as all subjects randomized and treated who have at least 1 concentration in at least 1 treatment period.	
End point type	Secondary
End point timeframe:	
Day 1 pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 9, 12, 24, 36, 48, 72 hours post dose in Period 1 and Period 2	

End point values	New Atorvastatin	Commercial Atorvastatin		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	73	75		
Units: hour				
median (full range (min-max))	0.5 (0.25 to 6.02)	0.5 (0.5 to 6)		

Statistical analyses

No statistical analyses for this end point

Secondary: Plasma Decay Half-Life (t1/2) of Atorvastatin

End point title	Plasma Decay Half-Life (t1/2) of Atorvastatin

End point description:

Plasma decay half-life was the time measured for the plasma concentration to decreased by one half of its initial concentration. The PK concentration population was defined as all subjects randomized and treated who have at least 1 concentration in at least 1 treatment period.

End point type	Secondary

End point timeframe:

Day 1 pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 9, 12, 24, 36, 48, 72 hours post dose in Period 1 and Period 2

End point values	New Atorvastatin	Commercial Atorvastatin		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	73	75		
Units: hour				
arithmetic mean (standard deviation)	6.059 (± 2.3267)	6.479 (± 2.0262)		

Statistical analyses

No statistical analyses for this end point

Secondary: Area Under the Curve Last (AUClast) of Ortho- hydroxyatorvastatin (o-hydroxyatorvastatin) and Para- hydroxyatorvastatin (p- hydroxyatorvastatin)

End point title	Area Under the Curve Last (AUClast) of Ortho-hydroxyatorvastatin (o- hydroxyatorvastatin) and Para-hydroxyatorvastatin (p- hydroxyatorvastatin)

End point description:

Area under the plasma concentration time-curve from zero to the last measured concentration (AUClast). The PK concentration population was defined as all subjects randomized and treated who have at least 1 concentration in at least 1 treatment period. Here, 'n' signifies those subjects who were evaluable for this measure.

End point type	Secondary

End point timeframe:

Day 1 pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 9, 12, 24, 36, 48, 72 hours post dose in Period 1 and Period 2

End point values	New Atorvastatin	Commercial Atorvastatin		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	73	75		
Units: ng*hr/mL				
geometric mean (geometric coefficient of variation)				
o- hydroxyatorvastatin (n=73, 75)	158.9 (± 43)	153.2 (± 42)		
p- hydroxyatorvastatin (n=72, 73)	9.704 (± 78)	8.602 (± 77)		

Statistical analyses

No statistical analyses for this end point

Secondary: Maximum Observed Plasma Concentration (Cmax) of Ortho-hydroxyatorvastatin (o-hydroxyatorvastatin) and Para- hydroxyatorvastatin (p-hydroxyatorvastatin)

End point title	Maximum Observed Plasma Concentration (Cmax) of Ortho-hydroxyatorvastatin (o-hydroxyatorvastatin) and Para-hydroxyatorvastatin (p-hydroxyatorvastatin)

End point description:

The PK concentration population was defined as all subjects randomized and treated who have at least 1 concentration in at least 1 treatment period. Here, 'n' signifies those subjects who were evaluable for this measure.

End point type	Secondary

End point timeframe:

0 to 72 hours post dose in Period 1 and Period 2

End point values	New Atorvastatin	Commercial Atorvastatin		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	73	75		
Units: ng/mL				
geometric mean (geometric coefficient of variation)				
o- hydroxyatorvastatin (n=73, 75)	22.33 (± 61)	22.42 (± 49)		
p- hydroxyatorvastatin (n=72, 73)	0.883 (± 66)	0.833 (± 58)		

Statistical analyses

No statistical analyses for this end point

Secondary: Time to Reach Maximum Observed Plasma Concentration (Tmax) of Ortho hydroxyatorvastatin (o-hydroxyatorvastatin) and Para hydroxyatorvastatin (p-hydroxyatorvastatin)

End point title	Time to Reach Maximum Observed Plasma Concentration (Tmax) of Ortho hydroxyatorvastatin (o-hydroxyatorvastatin) and Para hydroxyatorvastatin (p-hydroxyatorvastatin)

End point description:	
The PK concentration population was defined as all subjects randomized and treated who have at least 1 concentration in at least 1 treatment period. Here, 'n' signifies those subjects who were evaluable for this measure.	
End point type	Secondary
End point timeframe:	
Day 1 pre -dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 9, 12, 24, 36, 48, 72 hours post dose in Period 1 and Period 2	

End point values	New Atorvastatin	Commercial Atorvastatin		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	73	75		
Units: hour				
median (full range (min-max))				
o- hydroxyatorvastatin (n=73, 75)	1.017 (0.5 to 6.02)	1 (0.5 to 6)		
p- hydroxyatorvastatin (n=72, 73)	9 (0.5 to 72)	9 (0.5 to 12.1)		

Statistical analyses

No statistical analyses for this end point

Secondary: Area Under the Plasma Concentration Time Profile From Zero Extrapolated to Infinite Time (AUC inf) of Ortho-hydroxyatorvastatin (o-hydroxyatorvastatin)

End point title	Area Under the Plasma Concentration Time Profile From Zero Extrapolated to Infinite Time (AUC inf) of Ortho-hydroxyatorvastatin (o- hydroxyatorvastatin)
End point description:	
AUC (0 -- ∞)= Area under the plasma concentration versus time curve (AUC) from time zero (pre -dose) to extrapolated infinite time (0 - ∞). It is obtained from AUC (0 -- t) plus AUC (t - ∞). The PK concentration population was defined as all subjects randomized and treated who have at least 1 concentration in at least 1 treatment period.	
End point type	Secondary
End point timeframe:	
Day 1 pre- dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 9, 12, 24, 36, 48, 72 hours post dose in Period 1 and Period 2	

End point values	New Atorvastatin	Commercial Atorvastatin		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	73	75		
Units: ng*hr/mL				
geometric mean (geometric coefficient of variation)	163.5 (± 43)	157.8 (± 41)		

Statistical analyses

No statistical analyses for this end point

Secondary: Plasma Decay Half-Life (t1/2) of Ortho-hydroxyatorvastatin (o-hydroxyatorvastatin)

End point title	Plasma Decay Half-Life (t1/2) of Ortho-hydroxyatorvastatin (o-hydroxyatorvastatin)

End point description:

Plasma decay half-life was the time measured for the plasma concentration to decreased by one half of its initial concentration. The PK concentration population was defined as all subjects randomized and treated who have at least 1 concentration in at least 1 treatment period.

End point type	Secondary

End point timeframe:

Day 1 pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 9, 12, 24, 36, 48, 72 hours post dose in Period 1 and Period 2

End point values	New Atorvastatin	Commercial Atorvastatin		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	73	75		
Units: hour				
arithmetic mean (standard deviation)	8.681 (± 3.2453)	9.101 (± 4.2237)		

Statistical analyses

No statistical analyses for this end point

Other pre-specified: Number of Subjects With Treatment-Emergent Adverse Events (AEs) or Serious Adverse Events (SAEs)

End point title	Number of Subjects With Treatment-Emergent Adverse Events (AEs) or Serious Adverse Events (SAEs)

End point description:

An adverse event (AE) was any untoward medical occurrence in a participant who received study vaccine without regard to possibility of causal relationship. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death, initial or prolonged inpatient hospitalization, life-threatening experience (immediate risk of dying), persistent or significant disability or incapacity, congenital anomaly.

End point type	Other pre-specified

End point timeframe:

Baseline up to 28 days after last dose of study drug

End point values	New Atorvastatin	Commercial Atorvastatin		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	73	75		
Units: subjects				
number (not applicable)	19	14		

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information

Timeframe for reporting adverse events:

Baseline up to 30 days after the last administration of the study drug

Adverse event reporting additional description:

The same event may appear as both an adverse event (AE) and a serious AE (SAE). However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and non serious event during the study.

Assessment type	Non-systematic

Dictionary used

Dictionary name	MedDRA
Dictionary version	17.1

Reporting groups

Reporting group title	New Atorvastatin

Reporting group description:

Two new atorvastatin calcium chewable tablets of 40 mg administered in either first or second interventi on period.

Reporting group title	Commercial Atorvastatin

Reporting group description:

A single commercial atorvastatin tablet of 80 mg administered in either first or second intervention perio d.

Serious adverse events	New Atorvastatin	Commercial Atorvastatin	
Total subjects affected by serious adverse events			
subjects affected / exposed	0 / 73 (0.00%)	0 / 75 (0.00%)	
number of deaths (all causes)	0	0	
number of deaths resulting from adverse events	0	0	

Frequency threshold for reporting non-serious adverse events: 0 %

Non-serious adverse events	New Atorvastatin	Commercial Atorvastatin	
Total subjects affected by non-serious adverse events			
subjects affected / exposed	19 / 73 (26.03%)	14 / 75 (18.67%)	
Investigations			
Alanine aminotransferase increased			
subjects affected / exposed	0 / 73 (0.00%)	1 / 75 (1.33%)	
occurrences (all)	0	1	
Blood creatine phosphokinase increased			

subjects affected / exposed	0 / 73 (0.00%)	1 / 75 (1.33%)	
occurrences (all)	0	1	
Transaminases increased			
subjects affected / exposed	1 / 73 (1.37%)	1 / 75 (1.33%)	
occurrences (all)	1	1	
Injury, poisoning and procedural complications			
Contusion			
subjects affected / exposed	0 / 73 (0.00%)	1 / 75 (1.33%)	
occurrences (all)	0	1	
Muscle strain			
subjects affected / exposed	1 / 73 (1.37%)	0 / 75 (0.00%)	
occurrences (all)	1	0	
Nervous system disorders			
Dysgeusia			
subjects affected / exposed	1 / 73 (1.37%)	0 / 75 (0.00%)	
occurrences (all)	1	0	
Headache			
subjects affected / exposed	1 / 73 (1.37%)	2 / 75 (2.67%)	
occurrences (all)	2	2	
General disorders and administration site conditions			
Chest pain			
subjects affected / exposed	1 / 73 (1.37%)	0 / 75 (0.00%)	
occurrences (all)	1	0	
Fatigue			
subjects affected / exposed	1 / 73 (1.37%)	2 / 75 (2.67%)	
occurrences (all)	1	2	
Pain			
subjects affected / exposed	1 / 73 (1.37%)	0 / 75 (0.00%)	
occurrences (all)	1	0	
Pyrexia			
subjects affected / exposed	1 / 73 (1.37%)	0 / 75 (0.00%)	
occurrences (all)	1	0	
Gastrointestinal disorders			
Abdominal distension			
subjects affected / exposed	0 / 73 (0.00%)	1 / 75 (1.33%)	
occurrences (all)	0	1	

Diarrhoea			
subjects affected / exposed	4 / 73 (5.48%)	1 / 75 (1.33%)	
occurrences (all)	4	1	
Dyspepsia			
subjects affected / exposed	1 / 73 (1.37%)	0 / 75 (0.00%)	
occurrences (all)	1	0	
Flatulence			
subjects affected / exposed	0 / 73 (0.00%)	1 / 75 (1.33%)	
occurrences (all)	0	1	
Vomiting			
subjects affected / exposed	1 / 73 (1.37%)	0 / 75 (0.00%)	
occurrences (all)	1	0	
Reproductive system and breast disorders			
Dysmenorrhoea			
subjects affected / exposed	1 / 73 (1.37%)	0 / 75 (0.00%)	
occurrences (all)	1	0	
Respiratory, thoracic and mediastinal disorders			
Cough			
subjects affected / exposed	1 / 73 (1.37%)	1 / 75 (1.33%)	
occurrences (all)	1	1	
Epistaxis			
subjects affected / exposed	1 / 73 (1.37%)	0 / 75 (0.00%)	
occurrences (all)	1	0	
Oropharyngeal pain			
subjects affected / exposed	0 / 73 (0.00%)	2 / 75 (2.67%)	
occurrences (all)	0	2	
Sneezing			
subjects affected / exposed	1 / 73 (1.37%)	1 / 75 (1.33%)	
occurrences (all)	1	1	
Skin and subcutaneous tissue disorders			
Acne			
subjects affected / exposed	1 / 73 (1.37%)	0 / 75 (0.00%)	
occurrences (all)	1	0	
Hyperhidrosis			
subjects affected / exposed	1 / 73 (1.37%)	0 / 75 (0.00%)	
occurrences (all)	1	0	

Rash			
subjects affected / exposed	3 / 73 (4.11%)	3 / 75 (4.00%)	
occurrences (all)	3	3	
Psychiatric disorders			
Insomnia			
subjects affected / exposed	1 / 73 (1.37%)	1 / 75 (1.33%)	
occurrences (all)	1	1	
Musculoskeletal and connective tissue disorders			
Arthralgia			
subjects affected / exposed	1 / 73 (1.37%)	0 / 75 (0.00%)	
occurrences (all)	1	0	
Back pain			
subjects affected / exposed	1 / 73 (1.37%)	0 / 75 (0.00%)	
occurrences (all)	1	0	

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? No

---

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported